Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6751 to 6765 of 8314 results

  1. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    28 November 2007

  2. Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    27 March 2002

  3. Scleroderma: oral mycophenolate (ESUOM32)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    29 July 2014

  4. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants (IPG270)

    This guidance has been updated and replaced by NICE interventional procedures guidance 795.

    Interventional procedures guidance
    Published
    23 July 2008

  5. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1021.

    Technology appraisal guidance
    Published
    4 July 2018

  6. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)

    This guidance has been updated and replaced by NICE technology appraisal guidance 386.

    Technology appraisal guidance
    Published
    26 June 2013

  7. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    23 April 2008

  8. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

    This guidance has been updated and replaced by NICE technology appraisal guidance 975.  

    Technology appraisal guidance
    Published
    21 December 2018

  9. Interstitial cystitis: oral pentosan polysulfate sodium (ESUOM43)

    This guidance has been updated and replaced by NICE technology appraisal guidance 610.

    Evidence summary
    Published
    21 April 2015

  10. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    21 February 2017

  11. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection.

    Medtech innovation briefing
    Published
    8 May 2019

  12. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1038.

    Technology appraisal guidance
    Published
    3 November 2021

  13. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1040.

    Technology appraisal guidance
    Published
    2 February 2022

  14. Maternal and child nutrition (PH11)

    This guideline has been updated and replaced by NICE guideline NG247.

    Public health guideline
    Last updated
    1 November 2014

  15. Weight management: lifestyle services for overweight or obese children and young people (PH47)

    This guideline has been updated and replaced by NICE guideline NG246.

    Public health guideline
    Published
    23 October 2013